ONCOLYTICS BIOTECH INC. Deferred Income Tax Expense (Benefit)
ONCOLYTICS BIOTECH INC. (ONCY) reported Deferred Income Tax Expense (Benefit) of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2026-03-30
- ONCOLYTICS BIOTECH INC. deferred income tax expense (benefit) for fiscal 2025 was $0.00.
- ONCOLYTICS BIOTECH INC. deferred income tax expense (benefit) for fiscal 2024 was $0.00.
| Period end | Deferred Income Tax Expense (Benefit) 12 month |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-30 |
| 2024-12-31 | $0.00 10-K · filed 2026-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |